Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06440707 · ClinicalTrials.gov registry record · Phase 2
Transcranial Direct Current Stimulation for Treatment of Acute Ischemic Stroke
A Phase 2 study of Acute Ischemic Stroke, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 3
- Study locations
NCT06440707: Recruiting Phase 2 study of Acute Ischemic Stroke, sponsored by University of California, Los Angeles.
NCT06440707 is a Phase 2 study of Acute Ischemic Stroke that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 120 participants, below the 347-participant average among 25 other Acute Ischemic Stroke trials with a reported enrollment target (65% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06440707, a Phase 2 study of Acute Ischemic Stroke, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 3
- Study locations
Study Summary
Many patients with acute ischemic stroke are ineligible for currently available standard treatments (clot-busting medication, also known as intravenous thrombolytic or mechanical removal of a clot), and many are non-responders, resulting in a low rate of excellent outcomes, which necessitates the development of novel therapies. In this study, investigators are testing a new treatment in which a weak electrical current will be applied via scalp electrodes to increase collateral blood flow to the brain and rescue the brain tissue at risk of injury. The primary aim is to find an optimal dose of this therapy that is both adequately safe and effective on imaging markers of brain tissue rescue.
Primary Outcome
Presence of any intracranial hemorrhage on brain MRI, including hemorrhagic infarction types 1,2 and parenchymal hematoma types 1 and 2.
Conditions Studied
Interventions
- DEVICE High-definition Cathodal Transcranial Direct Current Stimulation (HD C-tDCS)
- DEVICE Sham tDCS
Study Locations (3)
California
- University of California- Los Angeles (UCLA) - Los Angeles
Maryland
- Johns Hopkins Medical Center - Baltimore
North Carolina
- Duke Medical Center Hospital - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-07-15 |
| Est. Completion | 2030-08-01 |
| Phase | Phase 2 |
What NCT06440707 shows while recruiting
NCT06440707 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 347-participant average among 25 other Acute Ischemic Stroke trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Acute Ischemic Stroke appearing as the primary indexed condition, and to 2 interventions - of which High-definition Cathodal Transcranial Direct Current Stimulation (HD C-tDCS) is the first listed.
NCT06440707 reports a single indexed study location in California, Maryland, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06440707 about?
NCT06440707 is a clinical study titled "Transcranial Direct Current Stimulation for Treatment of Acute Ischemic Stroke". Many patients with acute ischemic stroke are ineligible for currently available standard treatments (clot-busting medication, also known as intravenous thrombolytic or mechanical removal of a clot), and many are non-responders, resulting in a low rate of excellent outcomes, which necessitates the de...
What is the current status of trial NCT06440707?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2025-07-15. Estimated completion is 2030-08-01.
What conditions does trial NCT06440707 study?
This clinical trial studies the following conditions: Acute Ischemic Stroke.
What interventions are being tested in trial NCT06440707?
The interventions under investigation include: High-definition Cathodal Transcranial Direct Current Stimulation (HD C-tDCS) (DEVICE), Sham tDCS (DEVICE).
Who is sponsoring clinical trial NCT06440707?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06440707 being conducted?
This trial has 3 study locations across California, Maryland, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Ischemic Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06440707's enrollment target sits among peer trials
120 17th of 25 higher than 8 of 25 other Acute Ischemic Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Ischemic Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT
RECRUITING · Phase 2
-
Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)
RECRUITING · Phase 2
-
A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS
COMPLETED · Phase 2
-
A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI